Use of enzyme immunoassay to identify virus-specific antigens in studying a new anti-influenza preparation, arbidol

Leneva, I. A.; Fadeeva, N. I.; Fedyakina, I. Т.; Gus'kova, T. A.; Khristova, N.; Sokolova, Maria; Kharitonenkov, I G

doi:10.1007/bf02219196

Cited by 8 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier reports indicated that it inhibits the growth of influenza A and B viruses, RSV, and other respiratory viruses in cell culture (Table I) [Fadeeva et al, 1992;Glushkov et al, 1992;Leneva et al, 1994Leneva et al, , 2002Guskova and Glushkov, 1999]. Clinical studies demonstrated protection against influenza A virus infections with reductions in fever, duration of symptoms, and postinfluenza complications [Glushkov, 1992;Gagarinova et al, 1993;Glushkov et al, 1999].…”

Section: Discussionmentioning

confidence: 93%

“…Inhibition of influenza A and B virus replication in cell culture has been observed [Fadeeva et al, 1992;Glushkov et al, 1992;Leneva et al, 1994;Shi et al, 2007], although hemagglutination activity remained unchanged at concentrations that were sufficient to reduce plaque size [Glushkov et al, 1999]. More recently, it has been shown to inhibit hepatitis C virus [Boriskin et al, 2006].…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Antiviral activity of arbidol, a broad‐spectrum drug for use against respiratory viruses, varies according to test conditions

Brooks

Burtseva

Ellery

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

The therapeutic activity of arbidol was investigated against representatives of seven different virus families. Its 50% median effective concentration (EC(50) ) was 0.22-11.8 µg/ml (0.41-22 nM). Therapeutic indices of 91 were obtained for type 1 poliovirus and 1.9-8.5 for influenza A and B, human paramyxo-3, avian infectious bronchitis-, and Marek's disease viruses. Arbidol was more inhibitory for influenza A/Aichi/2/68 (H3N2) virus than rimantadine or amantadine (EC(50) 10 vs. >15 and >31.6 µg/ml); greater inhibition occurred when end-points were expressed as TCID(50) s. For respiratory syncytial virus (RSV), a reduction in plaque size but not number was observed. However, when the drug was added to infected cultures (≥5 µg/ml), a 3-log reduction in titer occurred. Arbidol did not inhibit directly influenza A/Aichi/2/68 hemagglutinin (HA) or neuraminidase (NA) activity, but inhibition of fusion between the viral envelope and chicken red blood cells occurred when added at 0.1 µg/ml prior to infection. Arbidol induced changes to viral mRNA synthesis of the PB2, PA, NP, NA, and NS genes in MDCK cultures infected with influenza A/PR/8/34. There was no indirect evidence of enhancement of interferon-α by arbidol following infection with A/Aichi/2/68. Arbidol neither reduced lung viral titers nor caused a significant reduction of lung consolidation in BALB/c mice after administration by the oral and intraperitoneal (i.p.) routes and intranasal challenge with influenza A/Aichi/2/68. A small reduction in lung consolidation, but not viral titer, occurred after i.p. administration and subsequent challenge with RSV. The results indicate the potential of arbidol as a broad-spectrum respiratory antiviral drug.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 96%

Antiviral activity of arbidol, a broad‐spectrum drug for use against respiratory viruses, varies according to test conditions

Brooks

Burtseva

Ellery

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Our study also showed that ARB could efficiently inhibit influenza infections when given after virus infection both in vitro and in vivo. It should be noted that post-treatment with ARB inhibited only 20% of viral reproduction during a one-cycle infection experiment as tested by fluorescence or EMIT [33] . In our experiment, post-treatment with the same concentration of ARB reduced the CPE by approximately 50% at 72 hpi.…”

Section: Discussionmentioning

confidence: 99%

Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection

et al. 2013

View full text Add to dashboard Cite

Aim: To investigate the effects of arbidol hydrochloride (ARB), a widely used antiviral agent, on the inflammation induced by influenza virus. Methods: MDCK cells were infected with seasonal influenza A/FM/1/47 (H1N1) or pandemic influenza A/Hubei/71/2009 (H1N1). In vitro cytotoxicity and antiviral activity of ARB was determined using MTT assay. BALB/c mice were infected with A/FM/1/47 (H1N1). Four hours later the mice were administered ARB (45, 90, and 180 mg·kg -1 ·d -1 ) or the neuraminidase inhibitor oseltamivir (22.5 mg·kg -1 ·d -1 ) via oral gavage once a day for 5 d. Body-weight, median survival time, viral titer, and lung index of the mice were measured. The levels of inflammatory cytokines were examined using real-time RT-PCR and ELISA. Results: Both H1N1 stains were equally sensitive to ARB as tested in vitro. In the infected mice, ARB (90 and 180 mg·kg -1 ·d -1 ) significantly decreased the mortality, alleviated virus-induced lung lesions and viral titers. Furthermore, ARB suppressed the levels of IL-1β, IL-6, IL-12, and TNF-α, and elevated the level of IL-10 in the bronchoalveolar lavage fluids and lung tissues. However, ARB did not significantly affect the levels of IFN-α and IFN-γ, but reduced the level of IFN-β1 in lung tissues at 5 dpi. In peritoneal macrophages challenged with A/FM/1/47 (H1N1) or poly I:C, ARB (20 µmol/L) suppressed the levels of IL-1β, IL-6, IL-12, and TNF-α, and elevated the level of IL-10. Oseltamivir produced comparable alleviation of virus-induced lung lesions with more reduction in the viral titers, but less effective modulation of the inflammatory cytokines. Conclusion: ARB efficiently inhibits both H1N1 stains and diminishes both viral replication and acute inflammation through modulating the expression of inflammatory cytokines.

show abstract

“…ARB exhibits a wide range and potent antiviral activity against a number of viruses including influenza A, B and C viruses [18], respiratory syncytial virus [19], adenovirus [20], parainfluenza type 5 and rhinovirus type 14 [21], avian coronavirus, infectious bronchitis virus and Marek disease virus [21], hepatitis B virus [22] and hepatitis C virus [23]. Recently, Chinese investigators confirmed the wide antiviral spectrum of ARB against influenza A, respiratory syncytial virus, human rhinovirus type 14, coxsackie B3 virus and adenovirus type 7 [24].…”

Section: Anti-viral Spectrum Of Arbmentioning

confidence: 99%

Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion

Boriskin

Ленева²,

Pécheur³

et al. 2008

CMC

372

316

View full text Add to dashboard Cite

Arbidol (ARB; ethyl-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-3-carboxylate hydrochloride monohydrate), is a Russian-made potent broad-spectrum antiviral with demonstrated activity against a number of enveloped and non-enveloped viruses. ARB is well known in Russia and China, although to a lesser extent in western countries. Unlike other broad-spectrum antivirals, ARB has an established molecular mechanism of action against influenza A and B viruses, which is different from that of available influenza antivirals, and a more recently established mechanism of inhibition of hepatitis C virus (HCV). For both viral infections the anti-viral mechanism involves ARB inhibition of virus-mediated fusion with target membrane and a resulting block of virus entry into target cells. However, ARB inhibition of fusion exploits different ARB modalities in case of influenza viruses or HCV. This review aims to summarize the available evidence of ARB effects against different groups of viruses, also, to compare various aspects of ARB anti-fusion mechanisms against influenza virus and HCV (with reference to different stringency of pH-dependence of these two viral fusogens) and to discuss further prospects for ARB and its improved derivatives of the parent compounds.

show abstract

Use of enzyme immunoassay to identify virus-specific antigens in studying a new anti-influenza preparation, arbidol

Cited by 8 publications

References 6 publications

Antiviral activity of arbidol, a broad‐spectrum drug for use against respiratory viruses, varies according to test conditions

Antiviral activity of arbidol, a broad‐spectrum drug for use against respiratory viruses, varies according to test conditions

Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection

Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion

Contact Info

Product

Resources

About